Summary:
A phase IIIB, 26 week, double blind, double dummy, randomized, parallel-group, mulitcenter study. Revealing the impact of Symbicort in reducing exacerbation in COPD.
Qualified Participants Must:
• Be 40 years of age or older
•
Have current diagnoses of moderate-severe COPD for more that 1 year
•
Be a current or previous smoker
•
Have had a moderate or severe COPD exacerbation that required treatment in the last year
•
NOT HAVE ASTHMA OR OTHER LUNG DISORDERS
Qualified Participants May Receive:
Study COPD medication, study related labs and exams, study related supplies and compensation at every visit.